Imagion Biosystems (ASX:IBX), which provides nanomagetic detection for cancer and other diseases, has contracted a nanoparticle manufacturer to produce its first formulations for clinical breast cancer studies.
The company entered into an agreement with a Dutch firm, ChemConnection BV, to produce and supply formulations for the company’s HER2 cancer test.
As part of the agreement the manufacturing organisation will establish procedures for Imagion’s MagSense technology, with safety toxicology studies to commence in the first quarter of next year.
The technology uses bio-safe nanoparticles to locate, tag and characterise cancers and tumours in their early stages.
The collaboration will allow the company to conduct its first human test next year.
Shares in Imagion Biosystems (ASX:IBX) are trading flat at 13.5 cents.